“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback